Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified dual therapy vs standard quadruple therapy for Helicobacter pylori: impact on gut microbiota
ChiCTR2300073037Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esomeprazole, amoxicillin, clarithromycin and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Intestinal microbiota and Intestinal microbiota resistance genes. Started Dec 2022; status: recruiting.
02
Drugs
esomeprazoleamoxicillinclarithromycinbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300073037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073037.